Neurology

FDA Warns of MS Worsening After Stopping Fingolimod (Gilenya)



The agency adds a new warning to the fingolimod label and patient medication guide about this risk, which can lead to permanent disability.
News Alerts

Source link

Related posts

Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases

Newsemia

Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial

Newsemia

neurosciencenews: Math + Good Posture = Better ScoresThese…

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy